| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/22/2004 | WO2004006897A1 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds |
| 01/22/2004 | WO2004006886A2 Injectable depot formulation comprising crystals of iloperidone |
| 01/22/2004 | WO2004006850A2 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| 01/22/2004 | WO2004006836A2 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds |
| 01/22/2004 | WO2004006830A2 Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 01/22/2004 | WO2004006662A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARα GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 01/22/2004 | WO2003097665A3 Mid 241 receptor, a novel g-protein coupled receptor |
| 01/22/2004 | WO2003089457A3 Peptide inhibitors of protein kinase c ϝ for pain management |
| 01/22/2004 | WO2003082813A3 Improvements in pharmaceutical compositions |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003060521A3 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 01/22/2004 | WO2003045316A3 Polynucleotide therapy |
| 01/22/2004 | WO2003024395A8 Linked biaryl compounds |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2002092573A3 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | WO2002072093A3 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | US20040014992 A dichlorobenzylcyanide or a dichlorophenylcyclohexyl acetic acid methyl ester; use as antagonist of serotonin receptor and dopamine, treating attention deficit hyperactivity disorder, Parkinson's disease, nervous system disorders |
| 01/22/2004 | US20040014983 Chlorinating benzisoxazole methane sulfonic acid with thionyl chloride to form an intermediate of benzisoxazole methane sulfonamide |
| 01/22/2004 | US20040014973 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines |
| 01/22/2004 | US20040014969 Such as methyl-4'-(4-((8-(acetylamino)ethyl)-2-naphthyl)oxy) butoxy)-(1,1'-biphenyl)-4-carboxylate; for treating/ preventing melatoninergic disorders |
| 01/22/2004 | US20040014967 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/22/2004 | US20040014810 Schizophrenia; dyskinesias |
| 01/22/2004 | US20040014809 Novel n-( 2-phenyl-3-aminopropyl)naphtamides |
| 01/22/2004 | US20040014802 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof |
| 01/22/2004 | US20040014796 Antiinflammatory agents; rheumatic diseases; antitumor agents |
| 01/22/2004 | US20040014793 Stability in blood |
| 01/22/2004 | US20040014788 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht receptor agonists |
| 01/22/2004 | US20040014787 Hormone inhibitors; controlling fertility |
| 01/22/2004 | US20040014786 Procee for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |
| 01/22/2004 | US20040014785 Cardiovascular disorders; antiischemic agents |
| 01/22/2004 | US20040014783 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 01/22/2004 | US20040014782 Combination therapy for the treatment of diseases involving inflammatory components |
| 01/22/2004 | US20040014780 Substituted ring-fused imidazole derivative: GABAA receptors ligands |
| 01/22/2004 | US20040014778 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 01/22/2004 | US20040014771 Synergistic mixture of antiserotonin agents and serotonin reuptake inhibitors; analgesics; irritable bowel syndrome |
| 01/22/2004 | US20040014770 Tachykinin antagonist |
| 01/22/2004 | US20040014769 Central nervous system disorders; antidepressants; anxiolytic agents; eating disorders |
| 01/22/2004 | US20040014768 Psychological disorders; schizophrenia |
| 01/22/2004 | US20040014767 Central nervous system diosrders; antidepressants, anxiolytic agents, anxiolytic agents |
| 01/22/2004 | US20040014760 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 01/22/2004 | US20040014755 Rho-kinase inhibitors |
| 01/22/2004 | US20040014748 Cardiovascular disorders, central nervous susyem disorders |
| 01/22/2004 | US20040014747 CRF receptor antagonists and methods relating thereto |
| 01/22/2004 | US20040014745 Amide compounds |
| 01/22/2004 | US20040014741 Dietetics; antidiabetic agents; antiinflammatory agents |
| 01/22/2004 | US20040014739 Low dosage; anxiolytic agents, psychological disorders, cognition activators |
| 01/22/2004 | US20040014725 Adjust diffusion of oxygen; respiratory system disorders; cardiovascular disorders |
| 01/22/2004 | US20040014721 Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 01/22/2004 | US20040014711 Cytidine diphosphate choline ester |
| 01/22/2004 | US20040014710 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 01/22/2004 | US20040014684 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic |
| 01/22/2004 | US20040014673 Pharmaceutical composition comprising an analgesic peptide |
| 01/22/2004 | US20040014672 Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/22/2004 | US20040014663 Botulinum toxin treatment for cervical dystonia |
| 01/22/2004 | US20040014662 Modulation of neural stem cells and neural progenitor cells |
| 01/22/2004 | US20040014660 Insulin-associated peptides with effects on cerebral health |
| 01/22/2004 | US20040014219 Comprises expression vector coding fusion protein associated cell proliferation and/or differentiation; gene therapy; animal model for disease |
| 01/22/2004 | US20040014141 Comprises transcription factor referred to as dragon protein (DRG) for treating and diagnosing nervous system, skin, muscle, bone and eye disorders |
| 01/22/2004 | US20040014111 Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases |
| 01/22/2004 | US20040014110 Dendritic enriched secreted lymphocyte activation molecule |
| 01/22/2004 | US20040014089 Culturing a transformant in a medium, allowing the polypeptide having phospholipase a2 activity fo form and accumulating in the culture, recovering the polypeptide thus formed |
| 01/22/2004 | US20040014057 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/22/2004 | US20040014037 Release factors (RF-1) polypeptides and DNA (RNA) encoding RF-1 polypetides and methods for producing such polypeptides by recombinant techniques; utilizing RF-1 polypeptides to screen for antibiotics |
| 01/22/2004 | US20040013746 Antidepressants for treating manic disorders, psychosis, comprising ethyl cellulose, talc, polyvinylpyrrolidone |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013716 Sustained release of drug antagonist; analgesic reservoir, barrier layer |
| 01/22/2004 | US20040013707 Alertness bar |
| 01/22/2004 | US20040013692 Use of botulinum toxins for treating various disorders and conditions and associated pain |
| 01/22/2004 | US20040013690 Attenuated Listeria spp. and methods for using the same |
| 01/22/2004 | US20040013680 Neurotoxic oligomers |
| 01/22/2004 | US20040013676 Administering dosage of mature dendritic cells in carrier |
| 01/22/2004 | US20040013648 Vector system |
| 01/22/2004 | US20040013637 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 01/22/2004 | DE10230750A1 Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten New pharmaceutical compositions based on new Anticholonergika and NK1 receptor antagonists |
| 01/22/2004 | DE10230381A1 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen Use of inhibitors of alanyl-aminopeptidase, and pharmaceutical preparations comprising them |
| 01/22/2004 | DE10228326A1 Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen Use of macrolide and / or tetracycline compounds and / or gyrase inhibitor-containing preparations for the prophylaxis and therapeutic treatment of migraine and migraine related disorders |
| 01/22/2004 | CA2843044A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | CA2833808A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/22/2004 | CA2743341A1 Drugs for treating or preventing brain injury and a method of screening the same |
| 01/22/2004 | CA2493373A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 01/22/2004 | CA2493372A1 Cinnamide derivatives |
| 01/22/2004 | CA2492781A1 Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| 01/22/2004 | CA2492725A1 Medicinal composition for drug-induced neuropathy |
| 01/22/2004 | CA2492720A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | CA2492694A1 Therapeutic or prophylactic agent for preventing nausea and vomiting |
| 01/22/2004 | CA2492485A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | CA2492433A1 Organic amine salts of poorly soluble probucol esters and ethers |
| 01/22/2004 | CA2492430A1 Phenylalanine enamide derivatives |
| 01/22/2004 | CA2492381A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | CA2492368A1 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492273A1 3, 10, and 12a substituted tetracycline compounds |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492046A1 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 01/22/2004 | CA2492029A1 Transdermal botulinum toxin compositions |
| 01/22/2004 | CA2492022A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds |
| 01/22/2004 | CA2491661A1 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |